Immunocore Holdings plc has announced its intention to offer $300 million aggregate principal amount of convertible senior notes due 2028 in a private offering. The notes will be available to qualified institutional buyers. The offering aims to raise capital, and the interest rate, initial conversion rate, and other terms will be determined at the time of pricing. Immunocore intends to use the net proceeds for general corporate purposes, including working capital, operating expenses, and capital expenditures. Additionally, the company may use a portion of the proceeds to invest in or acquire complementary businesses, products, or technologies, although it has no current commitments or agreements to do so.